The aim of this article is to describe the current and potential clinical translation of
pharmacological inhibitors of poly (ADP-ribose) polymerase (PARP) for the therapy of …

Neuroprotection for ischemic stroke refers to strategies, applied singly or in combination, that
antagonize the injurious biochemical and molecular events that eventuate in irreversible …

Cerebral ischemia (stroke) triggers a complex series of biochemical and molecular
mechanisms that impairs the neurologic functions through breakdown of cellular integrity …

Abstract Poly (ADP-ribose) polymerases (PARPs) are involved in the regulation of many
cellular functions. Three consequences of the activation of PARP1, which is the main isoform …

There is currently no approved neuroprotective pharmacotherapy for acute conditions such
as stroke and cerebral asphyxia. One of the reasons for this may be the multiplicity of cell …

Purpose: One mechanism of tumor resistance to cytotoxic therapy is repair of damaged
DNA. Poly (ADP-ribose) polymerase (PARP)-1 is a nuclear enzyme involved in base …

Poly (ADP-ribose) polymerases (PARPs) are defined as cell signaling enzymes that catalyze
the transfer of ADP-ribose units from NAD+ to a number of acceptor proteins. PARP-1, the …

Poly (ADP-ribose) polymerases (PARPs) are a family of enzymes that use NAD+ as a
substrate to synthesize polymers of ADP-ribose (PAR) as post-translational modifications of …

Parthanatos is a cell death signaling pathway in which excessive oxidative damage to DNA
leads to over-activation of poly (ADP-ribose) polymerase (PARP). PARP then generates the …

The poly (ADP-ribose) polymerase 1 (PARP1) enzyme is one of the promising molecular
targets for the discovery of antitumor drugs. PARP1 is a common nuclear protein (1-2 million …